公开(公告)号：US11529397B2

公开(公告)日：2022-12-20

申请号：US15876892

申请日：2018-01-22

申请人： Adriana M. Montaño-Suarez ,  Angela Catalina Sosa-Molano ,  Alan Knutsen ,  Clifford Bellone ,  Shunji Tomatsu ,  Luis Barrera

发明人： Adriana M. Montaño-Suarez ,  Angela Catalina Sosa-Molano ,  Alan Knutsen ,  Clifford Bellone ,  Shunji Tomatsu ,  Luis Barrera

IPC分类号： A61K39/00 ,  A61K38/46 ,  A61K9/00

摘要： Disclosed are methods and compositions for determining immunodominant peptides of target enzymes used in enzyme replacement therapy for lysosomal storage disorders. More specifically disclosed are immunodominant peptides for N-acetylgalactosamine-6-sulfatase (GALNS). Also disclosed are methods of inducing oral tolerance towards a target enzyme through oral administration of immunodominant peptides prior to commencing enzyme replacement therapy. More specifically disclosed is a method of inducing oral tolerance for GALNS, by orally administering specific immunodominant peptides for GALNS; in subjects suffering from mucopolysaccharidosis type IVA prior to commencing enzyme replacement therapy using GALNS.

公开(公告)号：US20190224283A1

公开(公告)日：2019-07-25

申请号：US15876892

申请日：2018-01-22

申请人： Adriana M. Montaño-Suarez ,  Angela Catalina Sosa-Molano ,  Alan Knutsen ,  Clifford Bellone ,  Shunji Tomatsu ,  Luis Barrera

发明人： Adriana M. Montaño-Suarez ,  Angela Catalina Sosa-Molano ,  Alan Knutsen ,  Clifford Bellone ,  Shunji Tomatsu ,  Luis Barrera

IPC分类号： A61K38/46 ,  A61K9/00

摘要： Disclosed are methods and compositions for determining immunodominant peptides of target enzymes used in enzyme replacement therapy for lysosomal storage disorders. More specifically disclosed are immunodominant peptides for N-acetylgalactosamine-6-sulfatase (GALNS). Also disclosed are methods of inducing oral tolerance towards a target enzyme through oral administration of immunodominant peptides prior to commencing enzyme replacement therapy. More specifically disclosed is a method of inducing oral tolerance for GALNS, by orally administering specific immunodominant peptides for GALNS; in subjects suffering from mucopolysaccharidosis type IVA prior to commencing enzyme replacement therapy using GALNS.